Typicality: | 0.606 |
Saliency: | 0.607 |
by administering qidssr16 | 3 | manner |
usually | 2 | temporal |
before starting the antiviral therapy | 2 | temporal |
depression → be → assessed | 55 |
depression → be → evaluated | 14 |
depression → be → examined | 4 |
negative | neutral | positive |
0.405 | 0.561 | 0.034 |
Raw frequency | 73 |
Normalized frequency | 0.607 |
Modifier score | 0.800 |
Perplexity | 184.111 |